LASA SUPERGENERICS LTD·Healthcare Companies·Pharmaceuticals & Biotechnology Companies

2026-08-21 NSE BSE Web 20% Result 15 Aug

Price

7.2

+3%
O:6.99
H:7.5
L:6.6
C:7.2

52W Range

5.6714.08
+27%/-49%

Market Cap

₹36.07 Cr

Traded: ₹0.03 Cr (0.07%) 0.0x

Free Float: ₹16.72 Cr (0.16% of FF traded)

Volume · 60D trend

37.77 K 0.0x

Delivery: % 0.0x

View Delivery Data

Returns

1W:+0% 1M:+5% 3M:-4% 6M:-15% 12M:-25%

Valuation

P/E--
P/B0.7
P/S5.7
EV/EBIT-51532704.3

Business Strength

ROE-19.6%
ROCE-18.2%
OPM-28.0%
NPM-136.0%

Growth (3Y CAGR)

EPS-130.5%
Sales-42.0%
Profit+10.0%
3Y Return-33.0%

Balance Sheet

Debt/Equity0.2
Debt9.75 Cr
Pledge20.7%
CWIP/Fixed Asset0.0%

Cash Position

CFO/NP0.0%
FCF0.15 Cr
FCF 3Y Avg5.57 Cr
Cash/MCap2.0%

Others

Div Yield0.0%
Div Payout0.0%
Cash Conv. Cycle-4 days
Tradeable Free Float46.4%

MTF Exposure Trend

37 sessions · funded amount, % of FF, daily delta

Current
₹ 0.16 L
0.01% FF
60d high
₹ 5.26 L
60d low
₹ 0
60d mean
₹ 1.66 L
vs mean
▼ 90.35%

Growth Trends

Metric10Y5Y3Y1YTTMTrend
Sales
--
-34.0%
-42.0%
--
-95.0%
Decelerating
ROE
+1.0%
-8.0%
-10.0%
--
--
Decelerating
Return
--
-35.0%
-33.0%
-24.0%
--
Accelerating
Profit
--
--
+10.0%
--
-547.0%
Decelerating

Quarterly Results

Jun 2026

15 Aug
Rev
1 Cr
-94% YoY+1046% QoQ
OPM-113.0%
NPM-291.1%
PAT
-467% YoY-4 Cr
EPS
+83% YoY-0.7

Mar 2026

PDF
Rev
-0 Cr
-100% YoY-106% QoQ
OPM--
NPM3200.0%
PAT
-139% YoY-4 Cr
EPS
+71% YoY-0.8

Dec 2025

PDF
Rev
2 Cr
-93% YoY-28% QoQ
OPM-34.1%
NPM-115.9%
PAT
-9% YoY-3 Cr
EPS
-146% YoY-0.5

Sep 2025

PDF
Rev
3 Cr
-92% YoY-85% QoQ
OPM-130.7%
NPM-204.3%
PAT
-94% YoY-6 Cr
EPS
-95% YoY-1.3

Jun 2025

PDF
Rev
20 Cr
-35% YoY-49% QoQ
OPM-2.5%
NPM-105.5%
PAT
+80% YoY-21 Cr
EPS
-681% YoY-4.2

Mar 2025

PDF
Rev
39 Cr
+72% YoY+18% QoQ
OPM8.7%
NPM-36.5%
PAT
+247% YoY-14 Cr
EPS
+7% YoY-2.9

Dec 2024

PDF
Rev
33 Cr
+24% YoY-16% QoQ
OPM0.8%
NPM16.6%
PAT
-60% YoY5 Cr
EPS
+479% YoY1.1

Sep 2024

PDF
Rev
39 Cr
+62% YoY+28% QoQ
OPM2.0%
NPM-8.2%
PAT
-16050% YoY-3 Cr
EPS
---0.6

Jun 2024

PDF
Rev
31 Cr
+1% YoY+35% QoQ
OPM5.8%
NPM-8.8%
PAT
+45% YoY-3 Cr
EPS
+45% YoY-0.5

Mar 2024

PDF
Rev
23 Cr
-35% YoY-14% QoQ
OPM-17.5%
NPM-67.0%
PAT
-233% YoY-15 Cr
EPS
-2% YoY-3.0

Dec 2023

PDF
Rev
27 Cr
--+10% QoQ
OPM4.0%
NPM-5.5%
PAT
+70% YoY-1 Cr
EPS
---0.3

Sep 2023

PDF
Rev
24 Cr
---20% QoQ
OPM4.3%
NPM-0.1%
PAT
+100% YoY-0 Cr
EPS
--0.0

Jun 2023

PDF
Rev
31 Cr
---13% QoQ
OPM13.3%
NPM-16.2%
PAT
+59% YoY-5 Cr
EPS
---1.0

Mar 2023

PDF
Rev
35 Cr
----
OPM12.3%
NPM-42.5%
PAT
-40% YoY-15 Cr
EPS
---3.0

Revenue & Margin Trends

Annual

Quarterly

Balance Sheet Health

Leverage

Debt / Equity0.20
Interest Coverage--x
Promoter Pledge20.7%
Borrowings10 Cr

Efficiency

Receivable Days1 days
Inventory Days28 days
Payable Days32 days
Cash Conversion cycle-4 days

Cash Position

Operating Cash Flow0 Cr
Investing Cash Flow0 Cr
Financing Cash Flow0 Cr
Free Cash Flow0 Cr

Detailed Financials

Jun 2026PDF ↗
Mar 2026PDF ↗
Dec 2025PDF ↗
Sep 2025PDF ↗
Jun 2025PDF ↗
Mar 2025PDF ↗
Dec 2024PDF ↗
Sep 2024PDF ↗
Jun 2024PDF ↗
Mar 2024PDF ↗
Dec 2023PDF ↗
Sep 2023PDF ↗
Jun 2023PDF ↗
Mar 2023PDF ↗
Sales1-02320393339312327243135
Expenses323721363339292726232731
Operating Profit-1-2-1-4-13012-41144
OPM %-113.0%---34.1%-130.7%-2.5%8.7%0.8%2.0%5.8%-17.5%4.0%4.3%13.3%12.3%
Other Income-0-000-20-22920-9000-19
Interest00000001110100
Depreciation21222433333334
Profit Before Tax-3-4-2-6-23-226-1-2-16-2-21-19
Tax %3.2%4.8%5.8%10.0%-6.3%-35.4%7.1%146.6%46.8%-4.2%-29.6%-99.0%580.6%-21.9%
Net Profit-4-4-3-6-21-145-3-3-15-1-0-5-15
Exceptional Items-0-000-21-24800-9000-20
EPS (Rs)-0.7-0.8-0.5-1.3-4.2-2.91.1-0.6-0.5-3.0-0.30.0-1.0-3.0
Sales Growth (YoY)-93.8%-100.3%-93.3%-92.2%-35.1%71.5%24.1%62.1%0.9%-35.4%--------
Sales Growth (QoQ)1046.2%-105.9%-28.1%-84.7%-48.9%18.3%-16.0%27.7%35.1%-14.4%9.7%-20.5%-13.5%--
OP Growth (YoY)-178.0%-162.2%-377.8%-606.3%-127.8%185.5%-74.5%-24.8%-55.6%-191.9%--------
OP Growth (QoQ)34.4%-182.7%81.3%-700.0%-114.7%1163.0%-65.8%-56.1%145.1%-476.4%1.0%-74.1%-6.7%--
Profit Growth (YoY)-467.0%-139.0%-9.0%-94.0%80.0%247.0%-60.0%-16050.0%45.0%-233.0%70.0%100.0%59.0%-40.0%
EPS Growth (YoY)83.2%70.9%-146.4%-95.3%-681.5%6.6%479.3%--45.5%-2.0%--------
EPS Growth (QoQ)14.5%-62.8%59.2%70.4%-48.1%-359.1%271.9%-18.5%82.3%-951.7%--100.0%66.9%--
OP Margin-113.0%1630.8%-34.1%-130.7%-2.5%8.7%0.8%2.0%5.8%-17.5%4.0%4.3%13.3%12.3%
Net Margin-291.1%3200.0%-115.9%-204.3%-105.5%-36.5%16.6%-8.2%-8.8%-67.0%-5.5%-0.1%-16.2%-42.5%
Material Cost %----102.7%180.7%78.4%72.4%74.1%79.4%71.5%81.0%74.8%67.9%66.4%71.8%
Employee Cost %----7.3%25.5%5.9%3.6%4.4%4.0%5.3%6.6%5.8%6.5%5.5%4.1%
P/S5.671.48------------------------
P/E----------------------------
P/B0.720.74------------------------

Shareholding Pattern

Shareholders:27.7K (-3.9%)
Current MixMar 2026

Exchange Filings

50
Company Update14 Aug 2026

Integrated filing for Quarter ended June 30, 2026

Board Meeting14 Aug 2026

Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held ....

Board Meeting04 Aug 2026

Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....

Insider Trading / SAST29 Jun 2026

Closure of trading window for the quarter ended June 30, 2026

Company Update30 May 2026

Annual Secretarial Compliance Report as on March 31st , 2026

Board Meeting29 May 2026

Outcome of board meeting for the quarter ended 31st march 2026

Board Meeting29 May 2026

Revised outcome of board meeting for quarter ended 31 march 2026

Company Update29 May 2026

Related party transaction as on 31 st march 2026

Company Update29 May 2026

Integrated filings as on 31st march, 2026

Board Meeting19 May 2026

Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....

Company Update12 May 2026

Certificate Reg 74 (5) of SEBI (DP) Regulations , 2018 as on 31st March 2026

Company Update16 Apr 2026

Declaration with respect to non- applicability of Large Entities

Insider Trading / SAST30 Mar 2026

Closure of trading window for the quarter and year ended March 31, 2026

Company Update13 Feb 2026

Integrated filing for quarter ended December 31, 2025

Result13 Feb 2026

Results for quarter ended 31st December 2025

Board Meeting13 Feb 2026

Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held ....

Board Meeting03 Feb 2026

Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....

Company Update15 Jan 2026

Certificate under Reg 74 (5) of SEBI (DP) Regulations, 2018

Others02 Jan 2026

Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today ....

Insider Trading / SAST29 Dec 2025

Closure of trading window for the quarter ended December 31, 2025

Company Update15 Dec 2025

We wish to inform you that Mrs. Mitti Jain is hereby appoitned as Company secretary and Compliance Officer of the Company

Company Update11 Dec 2025

We would llike to inform you that Mr. Prathmesh Chalke tendered his resignation as Whole-time Director of the Company .

Result14 Nov 2025

Results as on 30.09.2025

Company Update14 Nov 2025

Related party transaction as on 30.09.2025

Company Update14 Nov 2025

Integrated filing September 30, 2025

Board Meeting14 Nov 2025

Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held ....

Board Meeting10 Nov 2025

The Board Meeting to be held on 14/11/2025 has been revised to 14/11/2025 The Board Meeting to be held on 14/11/2025 has been revised to 14/11/2025

Board Meeting05 Nov 2025

Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve Pursuant to Regulation 29 ....

Company Update14 Oct 2025

Please find enclosed herewith certificate of 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended September, 30 2025 received from RTA Bigshare Services Private Limited

AGM/EGM01 Oct 2025

In terms of the subject referred the details regarding consolidated voting results of the business transacted at the 10th Annual General Meeting (AGM) of the company held on Tuesday 30th ....

AGM/EGM30 Sept 2025

Pursuant to Reg 30 SEBI (LODR), 2015 as amended we hereby submitting the summary of the proceedings of the 10 th AGM of the Company held on 30th September, 2025 at 11.00 AM and Concluded ....

Insider Trading / SAST29 Sept 2025

This is to inform you that as per the Company''s Code for Regulating, Monitoring and Reporting of Trading by the Insiders in terms of (prohibition of Insider trading )Regulations 2015, ....

Company Update22 Sept 2025

With the reference to the earlier disclosure submitted dated 29th August , 2025. We hereby submitting the revised Disclosure

Others05 Sept 2025

Annual Report for the financial year ended March 31, 2025 along with Notice of the Tenth (10th ) Annual General Meeting and Cut-off Date for the purpose of E voting

Others05 Sept 2025

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the Board of Directors at their meeting held today ....

AGM/EGM03 Sept 2025

We wish to informed you members of the Company has approved by way of postal ballot the resolution as set out in the Notice of Postal Ballot dated : 01.08.2025 with requisite majority

AGM/EGM03 Sept 2025

We wish to inform you that the members of the Company has approved by the way of postal ballot , the resolution under Companies Act 2013 and SEBI Listing Regulations as set out in the Notice ....

Company Update29 Aug 2025

With the reference to the Reg 30 of SEBI LODR resgulations, 2015 , we here inform you that Mrs Mitti Jain, Company Secretary and Compliance Officer of the Company has tendered her resignation ....

Company Update13 Aug 2025

Integrated filing June 2025

Result13 Aug 2025

Financials results as on June 30, 2025

Board Meeting13 Aug 2025

Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held ....

Board Meeting05 Aug 2025

Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 ,inter alia, to consider and approve Pursuant to Regulation 29 ....

Company Update05 Aug 2025

Pursuant to reg 30 SEBI (LODR) Regulations, 2015, we wolud like ti inform you about Board of Directors Meeting held today, 05th August, 2025 at 3.00 PM to 4.30 PM considered and approve ....

Others05 Aug 2025

Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today ....

Company Update04 Aug 2025

With the reference to above and in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby inform you that Mr. Ajay Sukhwani and Ms Ekta Gurnasinghani, Independent Director ....

AGM/EGM01 Aug 2025

Pursuant to Reg 30 SEBI (LODR) regulation, 2015 we enclose herewith postal ballot Notice , seeking approval of Members of the Company for below mentioned ordinary resolution

Company Update01 Aug 2025

With the reference to disclosure submitted on dated 31.07.2025, we hereby submit the revised Disclosure.

Company Update01 Aug 2025

With the reference to the above anf compliance with Reg 30 of SEBI (LODR) Regulations 2015, We hereby inform you that Mr. Hardesh Tolani , independent Director of the Company tender his ....

Company Update31 Jul 2025

With the reference compliance with Reg 30 of SEBI (LODR) Regulations 2015, We hereby inform that Ms Manali Bhagtani has tendered her resignation as Independent Director of the Company w.e.f ....

Company Update18 Jul 2025

Futher update on Factory Operations Post fire Incident

Annual Reports

9

2025

2024

2023

2022

2021

2020

2019

2018

2017

Concalls

7

Aug 2021

31 Aug 2021

Feb 2021

28 Feb 2021

Oct 2020

31 Oct 2020

Jun 2020

30 Jun 2020

Jun 2018

30 Jun 2018

Feb 2018

28 Feb 2018

Dec 2017

31 Dec 2017